GlassScriptPhysician profile
Joseph Barakeh
NPI 1013990613
$3,070.26
in general payments reported to CMS, 2019-2025
20 companies · $184 in 2025
The $184 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,550 · 2020: $42.57 · 2021: $202 · 2022: $327 · 2023: $371 · 2024: $394 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $931 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $930.92 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,489.54 | 2019-2022 | |
| Abbvie INC. | $303.77 | 2022-2025 | Durysta, Lumigan |
| Sun Pharmaceutical Industries INC. | $202.66 | 2020-2025 | Cequa |
| Harrow Eye, LLC | $185.18 | 2024 | Iheezo |
| Oyster Point Pharma, INC. | $121.01 | 2022-2024 | Tyrvaya, Tyrvaya, Ryzumvi |
| Alcon Vision LLC | $96.89 | 2021-2023 | Rocklatan |
| Carl Zeiss Meditec, INC. | $87.07 | 2019 | |
| Allergan, INC. | $77.65 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $66.41 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $64.43 | 2021 | |
| Bausch & Lomb Americas INC. | $62.05 | 2022-2023 | Prolensa, Vyzulta, Lotemax Sm |
| Sight Sciences, INC. | $59.48 | 2021-2024 | Omni Surgical System |
| Rxsight INC | $52.39 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Rayner Intraocular Lenses Limited | $45.88 | 2023 | Rayone Emv, Omidria, Rayone Aspheric |
| Thea Pharma INC. | $33.42 | 2024-2025 | Iyuzeh |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $32.57 | 2024 | Purified Cortrophin Gel |
| Iridex Corporation | $27.09 | 2019 | |
| Eyepoint US, INC. | $25.23 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Novartis Pharmaceuticals Corporation | $18.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Barakeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.